ATRA · XBRL financial data

Atara Biotherapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ATRA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25May 14, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	year only	27	29	40	33*	—	18	3	2*	1	1
Research and development	57	50*	46	33	44	29*	—	7	3	(0)*	0	1
General and administrative	12	11*	11	9	10	9*	—	7	4	4*	4	4
Other operating income (expense)	—	year only	1	1	0	0*	—	1	1	1*	1	0
Operating income (loss)	(70)	(60)*	(31)	(18)	(22)	(12)*	—	3	(4)	(3)*	(3)	(5)
Interest expense	1	1*	1	1	1	1*	—	1	1	1*	1	0
Other income (expense)	(0)	(0)*	0	(0)	1	(0)*	—	0	0	(0)*	0	0
Income tax expense (benefit)	(0)	0*	0	0	(0)	(0)*	—	0	0	0*	0	0
Net income (loss)	(70)	(60)*	(32)	(19)	(22)	(13)*	—	2	(4)	(3)*	(4)	(5)
Earnings per share, basic USD per share	(0.66)	(0.56)*	(0.23)	(3.10)	(2.93)	—	—	0.20	(0.32)	—	(0.29)	(0.32)
Earnings per share, diluted USD per share	(0.66)	(0.56)*	(0.23)	(3.10)	(2.93)	—	—	0.19	(0.32)	—	(0.29)	(0.32)
Weighted average shares, basic millions of shares	106	108*	141	6	7	—	—	12	14	14*	14	15
Weighted average shares, diluted millions of shares	106	108*	141	6	7	—	—	12	14	14*	14	15

† Share count changed about 1/24 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ATRA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25May 14, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	65	26	35	31	46	25	—	17	6	8	8	3
Short-term investments	38	26	11	4	21	17	—	5	8	0	—	7
Accounts receivable	0	34	36	2	1	1	—	0	2	1	0	0
Inventory	7	10	16	19	14	11	—	0	0	0	—	—
Total current assets	119	102	106	62	92	65	—	25	18	12	12	14
Property and equipment, net	5	4	3	2	2	1	—	0	0	0	0	0
Right-of-use asset	59	55	52	49	46	40	—	11	11	7	7	7
Total assets	189	166	165	117	143	109	—	37	30	20	20	21
Accounts payable	7	4	3	5	2	4	—	2	0	0	1	1
Accrued liabilities	8	19	18	11	8	6	—	5	3	2	2	2
Total current liabilities	79	142	181	148	156	135	—	15	18	15	6	7
Lease liability, non-current	49	46	42	39	35	30	—	15	15	9	9	9
Total liabilities	240	265	264	228	233	206	—	72	67	59	57	58
Accumulated deficit	(1,909)	(1,969)	(2,001)	(2,020)	(2,042)	(2,055)	—	(2,014)	(2,018)	(2,022)	(2,026)	(2,031)
Total stockholders' equity	(51)	(99)	(98)	(111)	(91)	(97)	—	(35)	(37)	(39)	(37)	(37)
Total liabilities and equity	189	166	165	117	143	109	—	37	30	20	20	21
Common shares outstanding (cover page) millions of shares	102	119	120	5	6	6	6	7	7	8	9	10

† Share count changed about 1/24 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ATRA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25May 14, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(70)	(60)*	(32)	(19)	(22)	(13)*	—	2	(4)	(3)*	(4)	(5)
Stock-based compensation	11*	10*	8	6*	6*	6*	—	3*	1*	2*	1	0*
Net cash from operating activities	(51)*	(50)*	(30)	(11)*	(4)*	(24)*	—	(7)*	(10)*	(6)*	(3)	(3)*
Purchases of property and equipment	0*	0*	0	0*	0*	0*	—	0*	0*	0*	—	—
Net cash from investing activities	70*	10*	15	7*	(17)*	3*	—	(5)*	(2)*	8*	0	(7)*
Proceeds from issuing common stock	0*	2*	9	(0)*	0*	0*	—	0*	1*	(0)*	3	5*
Net cash from financing activities	(0)*	2*	24	(0)*	36*	(0)*	—	15*	1*	(0)*	3	5*

† Share count changed about 1/24 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Atara Biotherapeutics	3.2	0.6	(3.3)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
CervoMed	22	0	(6.9)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
BriaCell Therapeutics	9.9	not reported	(6)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Abvc Biopharma	0	not reported	(0.2)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	55	33	(25)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Annovis Bio	19	0*	(22)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Actuate Therapeutics	4.4	not reported	(4.4)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	14	not reported	(3.2)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
Lite Strategy	5.7	not reported	(1.2)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.